JP2019534286A - 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド - Google Patents

放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド Download PDF

Info

Publication number
JP2019534286A
JP2019534286A JP2019522672A JP2019522672A JP2019534286A JP 2019534286 A JP2019534286 A JP 2019534286A JP 2019522672 A JP2019522672 A JP 2019522672A JP 2019522672 A JP2019522672 A JP 2019522672A JP 2019534286 A JP2019534286 A JP 2019534286A
Authority
JP
Japan
Prior art keywords
radiant energy
peptide
light
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534286A5 (enExample
Inventor
ジェンセン、スティーブン、ディー．
Original Assignee
カオ グループ、インク．
カオ グループ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カオ グループ、インク．, カオ グループ、インク． filed Critical カオ グループ、インク．
Publication of JP2019534286A publication Critical patent/JP2019534286A/ja
Publication of JP2019534286A5 publication Critical patent/JP2019534286A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019522672A 2016-10-26 2017-10-25 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド Pending JP2019534286A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662412938P 2016-10-26 2016-10-26
US62/412,938 2016-10-26
PCT/US2017/058267 WO2018081254A1 (en) 2016-10-26 2017-10-25 Cancer binding chromatic peptides that are targeted for disintegration by radiant energy

Publications (2)

Publication Number Publication Date
JP2019534286A true JP2019534286A (ja) 2019-11-28
JP2019534286A5 JP2019534286A5 (enExample) 2020-10-08

Family

ID=62025444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522672A Pending JP2019534286A (ja) 2016-10-26 2017-10-25 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド

Country Status (4)

Country Link
US (1) US20190275173A1 (enExample)
JP (1) JP2019534286A (enExample)
CN (1) CN109963874A (enExample)
WO (1) WO2018081254A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484442B (zh) 2018-06-01 2021-11-09 杭州阿诺生物医药科技有限公司 一种具有抗肿瘤活性的csf1r抑制剂中间体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015829A1 (en) * 2010-07-09 2016-01-21 The Usa As Represented By The Secretary, Department Of Health And Human Services Photosensitizing antibody-fluorophore conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058785A1 (en) * 2006-04-12 2008-03-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Autofluorescent imaging and target ablation
US20100183504A1 (en) * 2007-06-14 2010-07-22 Fanqing Frank Chen Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
JP6192799B2 (ja) * 2013-03-15 2017-09-06 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015829A1 (en) * 2010-07-09 2016-01-21 The Usa As Represented By The Secretary, Department Of Health And Human Services Photosensitizing antibody-fluorophore conjugates

Also Published As

Publication number Publication date
CN109963874A (zh) 2019-07-02
WO2018081254A1 (en) 2018-05-03
US20190275173A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
Khalkhal et al. The evaluation of laser application in surgery: a review article
US20100305436A1 (en) Systems, devices, and methods for photoactive assisted resection
Dougherty Photodynamic therapy—new approaches
Bown Photodynamic therapy for photochemists
US9550072B2 (en) Diagnostic device, therapeutic device, and uses thereof
US20120041305A1 (en) Light-emitting dye for intraoperative imaging or sentinel lymph node biopsy
KR101454939B1 (ko) 광선 역학적 치료(ｐｄｔ)를 이용한 이상 전기 전도 차단 장치
US20180093104A1 (en) Light irradiation method, light irradiation device, light irradiation system, device system for photodynamic diagnosis or photodynamic therapy, system for specifying tumor site and system for treating tumor
Pope et al. Photodynamic
Cortese et al. Hematoporphyrin-derivative phototherapy for local treatment of cancer of the tracheobronchial tree
JP2019534286A (ja) 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド
Pacifico et al. Nonsurgical management of Barrett's esophagus with high-grade dysplasia
WO2019244977A1 (ja) 腫瘍治療法
Carruth Photodynamic therapy: the state of the art
CN209361672U (zh) 一种可激发自体荧光的激光前列腺治疗系统
JP2019534285A (ja) 放射エネルギーによる崩壊の標的とされる癌結合性放射線不透過性ペプチド
Saidi et al. Nonthermal ablation of malignant esophageal strictures: photodynamic therapy, endoscopic intratumoral injections, and novel modalities
Palmer Treatment of common cutaneous tumors using the carbon dioxide laser
Kawaguchi et al. Two different methods of bronchial dissection and coverage in robotic bilobectomy for advanced lung cancer
BR112021017031B1 (pt) Dispositivo de fonte de luz, sistema de fonte de luz, câmera médica, dispositivo de diagnóstico fotodinâmico e dispositivo terapêutico fotodinâmico
Belmont et al. Effect of photodynamic therapy on revascularization of fasciocutaneous flaps
Brunetaud et al. Lasers in digestive endoscopy
US20060282133A1 (en) Method of Marking Biological Tissues for Enhanced Destruction by Applied Radiant Energy
Beamis Role of PDT and lasers in the tracheobronchial tree
Litle et al. Endoscopic Ablation of Barrett’s Esophagus and Early Esophageal Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308